Yatharth Hospital: ₹3,150 Crore Advent Investment Clears CCI, Expansion Returns Are the Real Test

12 November 2026  |  Yatharth Hospital & Trauma Care Services (NSE: YATHARTH)

Yatharth Hospital told stock exchanges on 12 November 2026 that the Competition Commission of India (CCI) has approved its proposed ₹3,150 crore preferential issue to Rasmalai Limited, an Advent International-backed investment vehicle. The transaction, first announced in September, would give the investor 24.87% of the company on a fully diluted post-issue basis. It is a substantial funding development for a hospital operator planning rapid expansion. But approval of the combination is not the same as the money having arrived: allotment and other closing conditions remain relevant.

₹3,150 Crore Preferential Issue: Price, Dilution and Timing

The September board disclosure set the subscription price at ₹985.17 per security. The structure covers up to roughly 1.30 crore equity shares and 1.89 crore convertible warrants, rather than an ordinary secondary purchase of shares from existing investors. Money subscribed into newly issued securities goes to the company; the warrants also mean some cash and share issuance can occur at a different stage from the initial equity allotment.

At the announced consideration and 24.87% fully diluted ownership, the implied post-money equity valuation works out to approximately ₹12,666 crore. That is a transaction-based calculation, not the current stock-market capitalisation or a fair-value target.

The CCI letter is dated 10 November. The company disclosed it on 12 November.

Yatharth Q2 FY27 Results: Fast Sales Growth, Modest PAT Growth

The funding news follows a strong September quarter. Consolidated revenue increased 52% year on year to ₹431.4 crore and EBITDA rose 50% to ₹102.0 crore. Profit after tax increased a slower 17% to ₹48.5 crore. 

Source: Yatharth Hospital Q2 FY27 earnings release, 3 November 2026. Rupee figures converted from the company’s ₹ million disclosures.

New Hospitals Drive Revenue, but the Reported Margin Remains Under Pressure

Newer hospitals accounted for ₹120.5 crore, or 28% of group revenue, up from an 11% contribution a year ago. Mature hospitals also grew 24%. Across the network, inpatient volumes increased 67% and average revenue per occupied bed (ARPOB) rose 11% to ₹35,948. Together, those figures explain why revenue is growing well ahead of the broader hospital market. Growth is coming from both adding facilities and getting more business out of beds already in use.

The more difficult part is profitability at the facilities still finding their feet. Group EBITDA margin slipped to 23.6% from 24.1% a year earlier, despite a 30 basis-point sequential improvement. Management disclosed a roughly 28% adjusted margin when excluding the ramp-up impact of New Delhi and Faridabad Sector-20. Opening hospitals costs money before occupancy catches up.

Faridabad Sector-20 and Agra were already EBITDA-positive in the first half, according to the company. New Delhi was expected to reach break-even in the second half of FY27. Each facility will need to demonstrate that the route from higher occupancy to cash earnings is working, rather than relying on the economics of older hospitals to carry the group.

Advent Capital and the 7,000–8,000 Bed Ambition

The company is looking to expand to approximately 7,000–8,000 beds over the next three to five years. The proposed investment is large enough to alter how quickly management can pursue that pipeline and how much incremental borrowing it may need. It also brings an experienced healthcare investor with governance rights, but the financing itself cannot settle questions of acquisition price, integration, hiring or ramp-up speed.

The critical economic chain is straightforward. New capital funds acquisitions and beds. Those beds need clinicians, equipment and patient volumes. Only after utilisation rises do operating leverage and returns on invested capital become visible. If the company expands too quickly, reported revenue can grow sharply while depreciation, working capital and low early-stage occupancy hold down PAT and free cash flow. That is the risk behind the opportunity.

Yatharth reported about ₹428.9 crore of cash and bank balances at the end of September 2026, prior to the proposed funding. First-half pre-tax operating cash flow was approximately ₹111.3 crore, up 49% year on year. These numbers provide a base to assess future funding needs, but cannot be directly compared with the ₹3,150 crore proposed issue as if all of it were already on the balance sheet.

Yatharth Share Valuation: Growth Already Commands a Premium

The stock was quoted at ₹1,042.70 on 11 November, with market capitalisation around ₹10,047 crore. Reported trailing P/E multiples differ across market-data platforms, so a precise multiple should not be presented as settled without one consistent calculation. The broad conclusion is clearer: Yatharth is not priced like a slow-growth hospital operator. Investors are already paying for rapid revenue growth and a much larger bed base in the years ahead.

At that valuation, the relevant question is not whether CCI approval is positive. It is whether acquired hospitals can lift occupancy and ARPOB fast enough to generate attractive returns after the new equity is issued. Cash-funded expansion may ease balance-sheet pressure, while dilution increases the earnings base needed to deliver comparable earnings per share. Those two effects need to be assessed together.

The Execution Measures That Matter After CCI Approval

The next disclosures should confirm the closing of the investment, the number of shares and warrants allotted, and the cash actually received. Beyond the transaction, focus on bed additions, mature versus new-hospital EBITDA margin, occupancy, ARPOB, depreciation and operating cash conversion. Sustained improvement in these measures would support the case for a larger, more profitable hospital platform.

The CCI clearance is a material step, but not a finished investment thesis. Yatharth has demonstrated that it can grow patient volumes and revenue rapidly. The issue now is whether it can bring new hospitals toward mature economics without letting capital intensity overwhelm the benefit. That will determine whether the ₹3,150 crore investment translates into genuine value per share.

Disclaimer: This article is analytical commentary for informational purposes and is not personalised investment advice.